ϟ
 
DOI: 10.1124/dmd.106.013391
OpenAccess: Closed
This work is not Open Acccess. We may still have a PDF, if this is the case there will be a green box below.

Pharmacokinetics and Metabolism of the Prodrug DB289 (2,5-Bis[4-(<i>N</i>-methoxyamidino)phenyl]furan Monomaleate) in Rat and Monkey and Its Conversion to the Antiprotozoal/Antifungal Drug DB75 (2,5-Bis(4-guanylphenyl)furan Dihydrochloride)

I. Midgley,K. Fitzpatrick,Lynne Taylor,Tara L. Houchen,Simon J. Henderson,Sarah Wright,Zbigniew R. Cybulski,B. A. John,A McBurney,David W. Boykin,Kerri L. Trendler

Prodrug
Pharmacokinetics
Bioavailability
2007
DB289 (pafuramidine maleate; 2,5-bis[4-(<i>N</i>-methoxyamidino)phenyl]furan monomaleate) is a prodrug of DB75 (furamidine dihydrochloride; 2,5-bis(4-guanylphenyl)furan dihydrochloride), an aromatic dication related to pentamidine that has demonstrated good efficacy against African trypanosomiasis, <i>Pneumocystis carinii</i> pneumonia, and malaria, but lacks adequate oral availability. The pharmacokinetics and metabolism of <sup>14</sup>C-DB289 have been investigated in rat and monkey after oral and intravenous administration. Oral doses were well absorbed (∼50-70%) and effectively converted to DB75 in both species but subject to first-pass metabolism and hepatic retention, limiting its systemic bioavailability to 10 to 20%. Clearance of DB289 approximated the liver plasma flow and its large volume of distribution was consistent with extensive tissue binding. Plasma protein binding of DB289 was 97 to 99% in four animal species and humans, but that of DB75 was noticeably less and more species- and concentration-dependent. Together, prodrug and active metabolite accounted for less than 20% of the plasma radioactivity after an oral dose, but DB75 was the major radiochemical component in key organs such as brain and liver and was largely responsible for the persistence of <sup>14</sup>C in the body. The predominant route of excretion of radioactivity was via the feces, although biliary secretion was not particularly extensive. High-performance liquid chromatography and liquid chromatography-mass spectrometry investigations showed that the formation of DB75 from the prodrug involved the sequential loss of the two <i>N</i>-methoxy groups, either directly or by <i>O-</i>demethylation followed by reduction of the resulting oxime to the amidine. It was estimated that almost half of an oral dose of DB289 to rats and about one-third of that to monkeys was metabolized to DB75.
Loading...
    Cite this:
Generate Citation
Powered by Citationsy*
    Pharmacokinetics and Metabolism of the Prodrug DB289 (2,5-Bis[4-(<i>N</i>-methoxyamidino)phenyl]furan Monomaleate) in Rat and Monkey and Its Conversion to the Antiprotozoal/Antifungal Drug DB75 (2,5-Bis(4-guanylphenyl)furan Dihydrochloride)” is a paper by I. Midgley K. Fitzpatrick Lynne Taylor Tara L. Houchen Simon J. Henderson Sarah Wright Zbigniew R. Cybulski B. A. John A McBurney David W. Boykin Kerri L. Trendler published in 2007. It has an Open Access status of “closed”. You can read and download a PDF Full Text of this paper here.